ArticleJournal of translational medicine2026
Dietary intake patterns and nutritional adequacy among adults with overweight or obesity treated with GLP-1 or dual GIP/GLP-1 receptor agonists- preliminary study.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGLP-1 dual GIP/GLP-1 agonists significantly suppress appetite, but it is unclear whether the typical diet of patients treated with these drugs still meets their basic nutritional need.
objectiveTo assess nutrients intake among adults undergoing pharmacotherapy and identify dietary predictors of weight loss efficacy.
methodsThis retrospective cohort study was conducted online among social media support groups (April 2024–February 2025). Participants included 387 adults, who reported regular once-weekly use of a GLP-1 agonist or dual GIP/GLP-1 agonist and completed 48-hour food diaries (one weekday and one weekend day). Daily energy and nutrient intake were reconstructed using a specialized software (Diet 6) containing an up-to-date database and standards issued by the National Institute of Public Health (NIZP PZH – PIB 2024). Differences between week and weekends were analyzed using a paired-samples t-test. Multiple linear regression assessed dietary and treatment predictors of weight loss.
resultsAverage energy intake was 753 kcal (SD 257.8 kcal), with protein 33.4 g (SD 15.3 g), fat 26.5 g (SD 12.4 g), carbohydrates 96.4 g (SD 35.6 g), and fiber 7.2 g (SD 3.1 g). Less than 10% of participants met the recommended intakes for protein. Weekday intake was significantly higher by 170 kcal (95%CI 152–185 kcal; p < 0.001), with greater consumption of fat (8–9 g), and sodium (370 mg). Higher total protein intake was “associated with more weight loss” (β = 0.446; p = 0.014), while a higher proportion of animal protein (β = − 0.517; p = 0.004) and higher sodium intake (β ≈ − 0.002; p = 0.013) were associated with less weight loss.
conclusionsAdults receiving GLP-1 pharmacotherapy exhibit insufficient protein and critical micronutrients, alongside excess fat and sodium intake on weekdays. Routine dietary education emphasizing protein adequacy and micronutrient sufficiency should accompany incretin therapy to prevent nutritional deficiencies, sarcopenia, and optimize weight loss outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.